EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kelisha capsule alleviates dextran sulfate sodium-induced acute colitis alongside changes in gut microbiota and PI3K/AKT phosphorylation

Shiyu Gao, Shihui Wang, Jieya Chen, Yingzi Hu, Jin Wu, Xia Liu, Guilin Ren, Zhenhui Zhang, Yu Song, Yingchao Liu

Frontiers in Pharmacology · 16.11.2026 · 17

DOI: 10.3389/fphar.2026.1969287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.11.2026. Verfasst von Shiyu Gao und 9 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kelisha capsule (KLS) is a licensed Chinese patent medicine for diarrhea and related gastrointestinal disorders, yet its activity in noninfectious colonic injury remains incompletely defined.

Methods

Three production batches were compared qualitatively by chromatography using borneol, eugenol, and piperine as markers. Batch 240506 was tested in male mice with dextran sulfate sodium (DSS)-induced acute colitis. Disease activity, histology, circulating cytokines, and tight-junction proteins were assessed. Fecal 16S rRNA gene sequencing and colonic RNA sequencing included Control, DSS, and high-dose KLS groups. Ereg mRNA and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) phosphorylation were examined by qPCR and immunoblotting, respectively. Donor fecal material transfer and YS49 coadministration during transfer or Akkermansia muciniphila administration were also evaluated.

Results

Chromatography showed qualitative concordance of the three markers. High-dose KLS improved disease activity, mucosal injury, and cytokine profiles and increased Occludin and Claudin-1 abundance. Treatment was accompanied by partial recovery of microbial diversity, an exploratory genus-level Akkermansia association, lower Ereg mRNA, and reduced p-PI3K/PI3K and p-AKT/AKT ratios. Recipients of KLS-treated donor material showed improved outcomes and a similar molecular pattern. YS49 coadministration was associated with higher phosphorylation ratios and worse outcomes.

Conclusion

KLS alleviated acute DSS colitis alongside microbial changes, lower Ereg mRNA, and reduced PI3K/AKT phosphorylation. These findings support its preclinical pharmacological activity and identify microbial and host responses for further mechanistic investigation.

Zitieren

APA

Gao, S., Wang, S., Chen, J., Hu, Y., Wu, J., Liu, X., Ren, G., Zhang, Z., Song, Y., & Liu, Y. (2026). Kelisha capsule alleviates dextran sulfate sodium-induced acute colitis alongside changes in gut microbiota and PI3K/AKT phosphorylation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1969287

Vancouver

Gao S, Wang S, Chen J, Hu Y, Wu J, Liu X, et al. Kelisha capsule alleviates dextran sulfate sodium-induced acute colitis alongside changes in gut microbiota and PI3K/AKT phosphorylation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1969287

BibTeX
@article{Gao2026,
  author = {Gao, Shiyu and Wang, Shihui and Chen, Jieya and Hu, Yingzi and Wu, Jin and Liu, Xia and Ren, Guilin and Zhang, Zhenhui and Song, Yu and Liu, Yingchao},
  title = {Kelisha capsule alleviates dextran sulfate sodium-induced acute colitis alongside changes in gut microbiota and PI3K/AKT phosphorylation},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1969287}
}
Kostenlos starten →